Farber disease (FD) is a debilitating lysosomal storage disorder (LSD) caused by a deficiency of acid ceramidase (ACDase) activity due to mutations in the gene ASAH1. Patients with ACDase deficiency may develop a spectrum of clinical phenotypes. Severe cases of FD are frequently associated with neurological involvement, failure to thrive, and respiratory complications. Mice homozygous ( Asah1P361R/P361R) for an orthologous patient mutation in Asah1 recapitulate human FD. In this study, we show significant impairment in lung function, including low compliance and increased airway resistance in a mouse model of ACDase deficiency. Impaired lung mechanics in Farber mice resulted in decreased blood oxygenation and increased red blood cell production. Inflammatory cells were recruited to both perivascular and peribronchial areas of the lung. We observed large vacuolated foamy histiocytes that were full of storage material. An increase in vascular permeability led to protein leakage, edema, and impacted surfactant homeostasis in the lungs of Asah1P361R/P361R mice. Bronchial alveolar lavage fluid (BALF) extraction and analysis revealed accumulation of a highly turbid lipoprotein-like substance that was composed in part of surfactants, phospholipids, and ceramides. The phospholipid composition of BALF from Asah1P361R/P361R mice was severely altered, with an increase in both phosphatidylethanolamine (PE) and sphingomyelin (SM). Ceramides were also found at significantly higher levels in both BALF and lung tissue from Asah1P361R/P361R mice when compared with levels from wild-type animals. We demonstrate that a deficiency in ACDase leads to sphingolipid and phospholipid imbalance, chronic lung injury caused by significant inflammation, and increased vascular permeability, leading to impaired lung function.

Department of Anesthesia University of Toronto Toronto Ontario Canada

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Physiology University of Toronto Toronto Ontario Canada

Departments of Pediatrics and Biochemistry Medical College of Wisconsin Milwaukee Wisconsin

Institute of Medical Science University of Toronto Toronto Ontario Canada

Institute of Pathology Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Keenan Research Centre for Biomedical Science Saint Michael's Hospital Toronto Ontario Canada

Laboratoire de Biochimie Métabolique Institut Fédératif de Biologie CHU Purpan and INSERM UMR1037 CRCT Université de Toulouse Toulouse France

Research Unit for Rare Diseases Department of Pediatrics and Adolescent Medicine Charles University 1st Faculty of Medicine Prague Czech Republic

University Health Network Toronto Ontario Canada

Zobrazit více v PubMed

Abul-Haj SK, Martz DG, Douglas WF, Geppert LJ. Farber’s disease. Report of a case with observations on its histogenesis and notes on the nature of the stored material. J Pediatr 61: 221–232, 1962. doi:10.1016/S0022-3476(62)80257-1. PubMed DOI

Ahmad A, Mazhar AU, Anwar M. Farber disease: a rare neurodegenerative disorder. J Coll Physicians Surg Pak 19: 67–68, 2009. 01.2009/JCPSP.6768. PubMed

Alayoubi AM, Wang JC, Au BC, Carpentier S, Garcia V, Dworski S, El-Ghamrasni S, Kirouac KN, Exertier MJ, Xiong ZJ, Privé GG, Simonaro CM, Casas J, Fabrias G, Schuchman EH, Turner PV, Hakem R, Levade T, Medin JA. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med 5: 827–842, 2013. doi:10.1002/emmm.201202301. PubMed DOI PMC

Antonarakis SE, Valle D, Moser HW, Moser A, Qualman SJ, Zinkham WH. Phenotypic variability in siblings with Farber disease. J Pediatr 104: 406–409, 1984. doi:10.1016/S0022-3476(84)81106-3. PubMed DOI

Balamayooran G, Batra S, Balamayooran T, Cai S, Jeyaseelan S. Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitment during Escherichia coli infection. Infect Immun 79: 2567–2577, 2011. doi:10.1128/IAI.00067-11. PubMed DOI PMC

Barrière H, Gillot F. [Farber’s lipogranulomatosis]. Nouv Presse Med 2: 767–770, 1972. PubMed

Bierman SM, Edgington T, Newcomer VD, Pearson CM. A disorder of mucopolysaccharide metabolism with articular, respiratory, and neurologic manifestations. Arthritis Rheum 9: 620–630, 1966.

Bjurulf B, Spetalen S, Erichsen A, Vanier MT, Strøm EH, Strømme P. Niemann-Pick disease type C2 presenting as fatal pulmonary alveolar lipoproteinosis: morphological findings in lung and nervous tissue. Med Sci Monit 14: CS71–CS75, 2008. PubMed

Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917, 1959. doi:10.1139/y59-099. PubMed DOI

Buccoliero R, Ginzburg L, Futerman AH. Elevation of lung surfactant phosphatidylcholine in mouse models of Sandhoff and of Niemann-Pick A disease. J Inherit Metab Dis 27: 641–648, 2004. doi:10.1023/B:BOLI.0000042958.22066.6c. PubMed DOI

Devi ARR, Gopikrishna M, Ratheesh R, Savithri G, Swarnalata G, Bashyam M. Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family. J Hum Genet 51: 811–814, 2006. doi:10.1007/s10038-006-0019-z. PubMed DOI

Dhami R, He X, Gordon RE, Schuchman EH. Analysis of the lung pathology and alveolar macrophage function in the acid sphingomyelinase—deficient mouse model of Niemann-Pick disease. Lab Invest 81: 987–999, 2001. doi:10.1038/labinvest.3780311. PubMed DOI

Dworski S, Lu P, Khan A, Maranda B, Mitchell JJ, Parini R, Di Rocco M, Hugle B, Yoshimitsu M, Magnusson B, Makay B, Arslan N, Guelbert N, Ehlert K, Jarisch A, Gardner-Medwin J, Dagher R, Terreri MT, Marques Lorenco C, Barillas-Arias L, Tanpaiboon P, Solyom A, Norris JS, He X, Schuchman EH, Levade T Medin JA. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. BBA Mol Basis Dis 186: 386–394, 2017. PubMed PMC

Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 5: 15, 2007. doi:10.1186/1546-0096-5-15. PubMed DOI PMC

Farber S, Cohen J, Uzman LL. Lipogranulomatosis; a new lipo-glycoprotein storage disease. J Mt Sinai Hosp N Y 24: 816–837, 1957. PubMed

Fiumara A, Nigro F, Pavone L, Moser HW. Farber disease with prolonged survival. J Inherit Metab Dis 16: 915–916, 1993. doi:10.1007/BF00714300. PubMed DOI

Ghidoni R, Caretti A, Signorelli P. Role of sphingolipids in the pathobiology of lung inflammation. Mediators Inflamm 2015: 487508, 2015. doi:10.1155/2015/487508. PubMed DOI PMC

Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze S, Gulbins E, Uhlig S. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 10: 155–160, 2004. doi:10.1038/nm977. PubMed DOI

Griese M, Brasch F, Aldana VR, Cabrera MM, Goelnitz U, Ikonen E, Karam BJ, Liebisch G, Linder MD, Lohse P, Meyer W, Schmitz G, Pamir A, Ripper J, Rolfs A, Schams A, Lezana FJ. Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Clin Genet 77: 119–130, 2010. doi:10.1111/j.1399-0004.2009.01325.x. PubMed DOI

Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 153: 176–184, 1996. doi:10.1164/ajrccm.153.1.8542113. PubMed DOI

Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 70: 673–683, 1982. doi:10.1172/JCI110662. PubMed DOI PMC

Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139–150, 2008. doi:10.1038/nrm2329. PubMed DOI

He X, Dworski S, Zhu C, DeAngelis V, Solyom A, Medin JA, Simonaro CM, Schuchman EH. Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clinc 7: 85–96, 2017. doi:10.1016/j.bbacli.2017.02.001. PubMed DOI PMC

Holm BA, Notter RH, Finkelstein JN. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids 38: 287–298, 1985. doi:10.1016/0009-3084(85)90022-2. PubMed DOI

Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol (1985) 63: 1434–1442, 1987. doi:10.1152/jappl.1987.63.4.1434. PubMed DOI

Ikegami M, Dhami R, Schuchman EH. Alveolar lipoproteinosis in an acid sphingomyelinase-deficient mouse model of Niemann-Pick disease. Am J Physiol Lung Cell Mol Physiol 284: L518–L525, 2003. doi:10.1152/ajplung.00258.2002. PubMed DOI

Ikegami M, Whitsett JA, Chroneos ZC, Ross GF, Reed JA, Bachurski CJ, Jobe AH. IL-4 increases surfactant and regulates metabolism in vivo. Am J Physiol Lung Cell Mol Physiol 278: L75–L80, 2000. doi:10.1152/ajplung.2000.278.1.L75. PubMed DOI

Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa H, Ando M. Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 14: 383–389, 1999. PubMed

Keough KM, Parsons CS, Phang PT, Tweeddale MG. Interactions between plasma proteins and pulmonary surfactant: surface balance studies. Can J Physiol Pharmacol 66: 1166–1173, 1988. doi:10.1139/y88-192. PubMed DOI

Kim YJ, Park SJ, Park CK, Kim SH, Lee CW. A case of Farber lipogranulomatosis. J Korean Med Sci 13: 95–98, 1998. doi:10.3346/jkms.1998.13.1.95. PubMed DOI PMC

Kuebler WM, Yang Y, Samapati R, Uhlig S. Vascular barrier regulation by PAF, ceramide, caveolae, and NO - an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem 26: 29–40, 2010. doi:10.1159/000315103. PubMed DOI

Levade T, Sandhoff K, Schulze H, Medin J. Acid ceramidase deficiency: farber lipogranulomatosis. In: Scriver’s OMMBID (Online Metabolic and Molecular Bases of Inherited Diseases), edited by Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, and Ballabio A). New York: McGraw-Hill, 2014, Ch. 143.

Li CM, Park JH, He X, Levy B, Chen F, Arai K, Adler DA, Disteche CM, Koch J, Sandhoff K, Schuchman EH. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics 62: 223–231, 1999. doi:10.1006/geno.1999.5940. PubMed DOI

Loiseau N, Polizzi A, Dupuy A, Therville N, Rakotonirainy M, Loy J, Viadere JL, Cossalter AM, Bailly JD, Puel O, Kolf-Clauw M, Bertrand-Michel J, Levade T, Guillou H, Oswald IP. New insights into the organ-specific adverse effects of fumonisin B1: comparison between lung and liver. Arch Toxicol 89: 1619–1629, 2015. doi:10.1007/s00204-014-1323-6. PubMed DOI

Moser HW, Prensky AL, Wolfe HJ, Rosman NP. Farber’s lipogranulomatosis. Report of a case and demonstration of an excess of free ceramide and ganglioside. Am J Med 47: 869–890, 1969. doi:10.1016/0002-9343(69)90202-2. PubMed DOI

Mura M, Binnie M, Han B, Li C, Andrade CF, Shiozaki A, Zhang Y, Ferrara N, Hwang D, Waddell TK, Keshavjee S, Liu M. Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am J Pathol 176: 1725–1734, 2010. doi:10.2353/ajpath.2010.090209. PubMed DOI PMC

Patel BV, Wilson MR, O’Dea KP, Takata M. TNF-induced death signaling triggers alveolar epithelial dysfunction in acute lung injury. J Immunol 190: 4274–4282, 2013. doi:10.4049/jimmunol.1202437. PubMed DOI PMC

Pellissier JF, Berard-Badier M, Pinsard N. Farber’s disease in two siblings, sural nerve and subcutaneous biopsies by light and electron microscopy. Acta Neuropathol 72: 178–188, 1986. doi:10.1007/BF00685981. PubMed DOI

Petrache I, Berdyshev EV. Ceramide signaling and metabolism in pathophysiological states of the lung. Annu Rev Physiol 78: 463–480, 2016. doi:10.1146/annurev-physiol-021115-105221. PubMed DOI

Petrache I, Kamocki K, Poirier C, Pewzner-Jung Y, Laviad EL, Schweitzer KS, Van Demark M, Justice MJ, Hubbard WC, Futerman AH. Ceramide synthases expression and role of ceramide synthase-2 in the lung: insight from human lung cells and mouse models. PLoS One 8: e62968, 2013. doi:10.1371/journal.pone.0062968. PubMed DOI PMC

Pewzner-Jung Y, Tavakoli Tabazavareh S, Grassmé H, Becker KA, Japtok L, Steinmann J, Joseph T, Lang S, Tuemmler B, Schuchman EH, Lentsch AB, Kleuser B, Edwards MJ, Futerman AH, Gulbins E. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa. EMBO Mol Med 6: 1205–1214, 2014. doi:10.15252/emmm.201404075. PubMed DOI PMC

Rauvala H, Hallman M. Glycolipid accumulation in bronchoalveolar space in adult respiratory distress syndrome. J Lipid Res 25: 1257–1262, 1984. PubMed

Ryan AJ, McCoy DM, McGowan SE, Salome RG, Mallampalli RK. Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity. J Appl Physiol (1985) 94: 253–258, 2003. doi:10.1152/japplphysiol.00184.2002. PubMed DOI

Samuelsson K, Zetterström R, Ivemark B.. Studies on a case of lipogranulomatosis (Farber’s disease) with protracted course. In: Sphingolipids, Sphingolipidoses and Allied Disorders, edited by Volk B and Aronson S. New York: Springer, 1972, p. 533–548.

Samuelsson K, Zetterström R. Ceramides in a patient with lipogranulomatosis (Farber’s disease) with chronic course. Scand J Clin Lab Invest 27: 393–405, 1971. doi:10.3109/00365517109080235. PubMed DOI

Schneider EL, Epstein CJ, Kaback MJ, Brandes D. Severe pulmonary involvement in adult Gaucher’s disease. Report of three cases and review of the literature. Am J Med 63: 475–480, 1977. doi:10.1016/0002-9343(77)90288-1. PubMed DOI

Schuchman EH. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. Biochim Biophys Acta 1862: 1459–1471, 2016. doi:10.1016/j.bbadis.2016.05.001. PubMed DOI

Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 6: 971–977, 1993. PubMed

Seeger W, Stöhr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) 58: 326–338, 1985. doi:10.1152/jappl.1985.58.2.326. PubMed DOI

Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 166: 215–235, 2002. doi:10.1164/rccm.2109105. PubMed DOI

Sheth J, Joseph JJ, Shah K, Muranjan M, Mistri M, Sheth F. Pulmonary manifestations in Niemann-Pick type C disease with mutations in NPC2 gene: case report and review of literature. BMC Med Genet 18: 5, 2017. doi:10.1186/s12881-017-0367-x. PubMed DOI PMC

Sideris GA, Josephson M. Pulmonary alveolar proteinosis and Niemann Pick disease type B: An unexpected combination. Respir Med Case Rep 19: 37–39, 2016. doi:10.1016/j.rmcr.2016.06.009. PubMed DOI PMC

Sikora J, Dworski S, Jones EE, Kamani MA, Micsenyi MC, Sawada T, Le Faouder P, Bertrand-Michel J, Dupuy A, Dunn CK, Yang Xuan Ingrid C, Casas J, Fabrias G, Hampson DR, Levade T, Drake Richard R, Medin JA, Walkley SU. Acid ceramidase deficiency in mice results in a broad range of central nervous system abnormalities. Am J Pathol 187: 864–883, 2017. PubMed PMC

Sommer U, Herscovitz H, Welty FK, Costello CE. LC-MS-based method for the qualitative and quantitative analysis of complex lipid mixtures. J Lipid Res 47: 804–814, 2006. doi:10.1194/jlr.M500506-JLR200. PubMed DOI

Standiford TJ, Kunkel SL, Lukacs NW, Greenberger MJ, Danforth JM, Kunkel RG, Strieter RM. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol 155: 1515–1524, 1995. PubMed

Sugita M, Dulaney JT, Moser HW. Ceramidase deficiency in Farber’s disease (lipogranulomatosis). Science 178: 1100–1102, 1972. doi:10.1126/science.178.4065.1100. PubMed DOI

Tanaka T, Takahashi K, Hakozaki H, Kimoto H, Suzuki Y. Farber’s disease (disseminated lipogranulomatosis)—a pathological, histochemical and ultrastructural study. Acta Pathol Jpn 29: 135–155, 1979. PubMed

Tibboel J, Reiss I, de Jongste JC, Post M. Sphingolipids in lung growth and repair. Chest 145: 120–128, 2014. doi:10.1378/chest.13-0967. PubMed DOI

Toppet M, Vamos-Hurwitz E, Jonniaux G, Cremer N, Tondeur M, Pelc S. Farber’s disease as a ceramidosis: clinical, radiological and biochemical aspects. Acta Paediatr Scand 67: 113–119, 1978. doi:10.1111/j.1651-2227.1978.tb16287.x. PubMed DOI

Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 178: 1100–1114, 2008. doi:10.1164/rccm.200804-595SO. PubMed DOI

Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, Anderson SJ, Sun W, Swaffield J, Oravecz T. Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4: e4112, 2009. doi:10.1371/journal.pone.0004112. PubMed DOI PMC

Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 77: 39–45, 2009. doi:10.1016/j.mvr.2008.09.005. PubMed DOI PMC

Weaver TE, Na CL, Stahlman M. Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin Cell Dev Biol 13: 263–270, 2002. doi:10.1016/S1084952102000551. PubMed DOI

Yang G, Hamacher J, Gorshkov B, White R, Sridhar S, Verin A, Chakraborty T, Lucas R. The dual role of TNF in pulmonary edema. J Cardiovasc Dis Res 1: 29–36, 2010. doi:10.4103/0975-3583.59983. PubMed DOI PMC

Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis 5: 325–344, 2011. doi:10.1177/1753465811406772. PubMed DOI

Yang Y, Yin J, Baumgartner W, Samapati R, Solymosi EA, Reppien E, Kuebler WM, Uhlig S. Platelet-activating factor reduces endothelial nitric oxide production: role of acid sphingomyelinase. Eur Respir J 36: 417–427, 2010. doi:10.1183/09031936.00095609. PubMed DOI

Yeager AM, Armfield Uhas K, Coles CD, Davis PC, Krause WL, Moser HW. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant 26: 357–363, 2000. doi:10.1038/sj.bmt.1702489. PubMed DOI

Zetterström R. Disseminated lipogranulomatosis (Farber’s disease). Acta Paediatr 47: 501–510, 1958. doi:10.1111/j.1651-2227.1958.tb07665.x. PubMed DOI

Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency

Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency

Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment